These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33254031)
1. Reverse genetics for influenza B viruses and recent advances in vaccine development. Cardenas-Garcia S; Caceres CJ; Rajao D; Perez DR Curr Opin Virol; 2020 Oct; 44():191-202. PubMed ID: 33254031 [TBL] [Abstract][Full Text] [Related]
2. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951 [TBL] [Abstract][Full Text] [Related]
3. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine. Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124 [TBL] [Abstract][Full Text] [Related]
4. Reverse Genetics Approaches for the Development of Influenza Vaccines. Nogales A; Martínez-Sobrido L Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025504 [TBL] [Abstract][Full Text] [Related]
5. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B. McKeage K Drugs; 2013 Sep; 73(14):1587-94. PubMed ID: 24022123 [TBL] [Abstract][Full Text] [Related]
6. Development of an Alternative Modified Live Influenza B Virus Vaccine. Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580 [TBL] [Abstract][Full Text] [Related]
8. The coming era of quadrivalent human influenza vaccines: who will benefit? Barr IG; Jelley LL Drugs; 2012 Dec; 72(17):2177-85. PubMed ID: 23110610 [TBL] [Abstract][Full Text] [Related]
9. A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines. White CL; Chiem K; Perez DR; Santos J; Cardenas Garcia S; Nogales A; Martínez-Sobrido L Viruses; 2021 Jun; 13(7):. PubMed ID: 34208979 [TBL] [Abstract][Full Text] [Related]
10. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Reed C; Meltzer MI; Finelli L; Fiore A Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861 [TBL] [Abstract][Full Text] [Related]
12. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H mBio; 2019 Sep; 10(5):. PubMed ID: 31530680 [TBL] [Abstract][Full Text] [Related]
13. [DEVELOPMENT OF THE QUADRIVALENT LIVE ATTENUATED INFLUENZA VACCINE INCLUDING TWO INFLUENZA B LINEAGES--VICTORIA AND YAMAGATA]. Desheva YA; Smolonogina TA; Doroshenko EM; Rudenko LG Vopr Virusol; 2016; 61(1):16-20. PubMed ID: 27145595 [TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Bandell A; Woo J; Coelingh K Expert Rev Vaccines; 2011 Aug; 10(8):1131-41. PubMed ID: 21854309 [TBL] [Abstract][Full Text] [Related]
15. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season. Grohskopf LA; Blanton LH; Ferdinands JM; Chung JR; Broder KR; Talbot HK; Morgan RL; Fry AM MMWR Recomm Rep; 2022 Aug; 71(1):1-28. PubMed ID: 36006864 [TBL] [Abstract][Full Text] [Related]
17. Influenza vaccines. Brede HD Int Arch Allergy Immunol; 1995 Dec; 108(4):318-20. PubMed ID: 7580301 [TBL] [Abstract][Full Text] [Related]
18. [Burden of influenza virus type B and mismatch with the flu vaccine in Spain]. Eiros-Bouza JM; Pérez-Rubio A Rev Esp Quimioter; 2015 Feb; 28(1):39-46. PubMed ID: 25690144 [TBL] [Abstract][Full Text] [Related]
19. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Pebody R; Warburton F; Ellis J; Andrews N; Potts A; Cottrell S; Johnston J; Reynolds A; Gunson R; Thompson C; Galiano M; Robertson C; Byford R; Gallagher N; Sinnathamby M; Yonova I; Pathirannehelage S; Donati M; Moore C; de Lusignan S; McMenamin J; Zambon M Euro Surveill; 2016 Sep; 21(38):. PubMed ID: 27684603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]